trabectedin (yondelis) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia turbinata. Trabectedin was approved for the treatment of liposarcoma or leiomyosarcoma (USA and Europe) and ovarian cancer (only in Europe). Trabectedin exerts its anti-cancer action by binding guanine residues in the minor groove of DNA. The binding prevents DNA from interacting with transcription factors and the reparation system and results in perturbation of the cell cycle and eventual cell death.   NCATS

Chemistry

  • SMILES: [H][C@@]12[C@@H]3SC[C@]4(NCCC5=C4C=C(OC)C(O)=C5)C(=O)OC[C@H](N1[C@@H](O)[C@@H]6CC7=C([C@H]2N6C)C(O)=C(OC)C(C)=C7)C8=C9OCOC9=C(C)C(OC(C)=O)=C38
  • InChIKey: PKVRCIRHQMSYJX-AIFWHQITSA-N
  • Mol. Mass: 761.837
  • ALogP: 3.41
  • ChEMBL Molecule:
    trabectedin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2266.3200 - $2877.8600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ecteinascidin | ecteinascidin 743 | ecteinascidine | et 743 | et-743 | nsc 684766 | trabectedin | yondelis

Organizations (61)

Research & Development (60)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (41)

Approved Indications (3)


 

Leiomyosarcoma (approved 2015)

Liposarcoma (approved 2015)

Ovarian Neoplasms (approved 2007)

Experimental Indications - Clinical Trial Phases 1-4 (41)


 

Adnexal Diseases (Phase 2)

Brain Neoplasms (Phase 2)

BRCA1 Protein (Phase 2)

Breast Diseases (Phase 2)

Breast Neoplasms (Phase 2)

Chondrosarcoma, Mesenchymal (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Endocrine Gland Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Gastrointestinal Stromal Tumors (Phase 2)

Genital Diseases, Female (Phase 2)

Hamartoma (Phase 2)

Hepatic Insufficiency (Phase 1)

Hyperlipidemias (Phase 1)

Intestinal Neoplasms (Phase 2)

Leiomyosarcoma (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Liposarcoma (Phase 3)

Liposarcoma, Myxoid (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1)

Meningioma (Phase 2)

Mesothelioma, Malignant (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms by Histologic Type (Phase 1)

Neoplasms by Site (Phase 2)

Neoplasms, Connective and Soft Tissue (Phase 1)

Neuroectodermal Tumors, Primitive, Peripheral (Phase 2)

Ovarian Diseases (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Ewing (Phase 2)

Sarcoma, Synovial (Phase 3)

Skin Diseases (Phase 2)

Solitary Fibrous Tumors (Phase 2)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 82
  • # of Trial Organizations: 60

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue